- Home
- NPCE vs ENTA Comparison
NPCE vs ENTA Comparison
Compare NPCE & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- ENTA
- Stock Information
- Founded
- NPCE 1997
- ENTA 1995
- Country
- NPCE United States
- ENTA United States
- Employees
- NPCE N/A
- ENTA N/A
- Industry
- NPCE Medical Specialities
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- NPCE Health Care
- ENTA Health Care
- Exchange
- NPCE Nasdaq
- ENTA Nasdaq
- Market Cap
- NPCE 328.8M
- ENTA 316.2M
- IPO Year
- NPCE 2021
- ENTA 2013
- Fundamental
- Price
- NPCE $9.38
- ENTA $11.17
- Analyst Decision
- NPCE Strong Buy
- ENTA Strong Buy
- Analyst Count
- NPCE 6
- ENTA 5
- Target Price
- NPCE $16.67
- ENTA $21.00
- AVG Volume (30 Days)
- NPCE 121.6K
- ENTA 474.7K
- Earning Date
- NPCE 11-04-2025
- ENTA 11-17-2025
- Dividend Yield
- NPCE N/A
- ENTA N/A
- EPS Growth
- NPCE N/A
- ENTA N/A
- EPS
- NPCE N/A
- ENTA N/A
- Revenue
- NPCE $88,570,000.00
- ENTA $64,806,000.00
- Revenue This Year
- NPCE $22.13
- ENTA $0.07
- Revenue Next Year
- NPCE $6.07
- ENTA N/A
- P/E Ratio
- NPCE N/A
- ENTA N/A
- Revenue Growth
- NPCE 23.32
- ENTA N/A
- 52 Week Low
- NPCE $6.03
- ENTA $4.09
- 52 Week High
- NPCE $18.98
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- NPCE 35.09
- ENTA 56.42
- Support Level
- NPCE $9.22
- ENTA $10.44
- Resistance Level
- NPCE $10.81
- ENTA $11.45
- Average True Range (ATR)
- NPCE 0.44
- ENTA 0.62
- MACD
- NPCE -0.18
- ENTA -0.08
- Stochastic Oscillator
- NPCE 6.09
- ENTA 52.09
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.